


Company Overview:

Oncoscope develops diagnostic systems that use proprietary optical technologies to locate pre-cancerous cells in epithelial tissues where 85% of all cancers begin. These devices are fast, accurate, non-invasive, and allow the examination of large tissue areas. Most importantly, Oncoscope's technology detects early pre-cancerous dysplasia, a breakthrough over existing diagnostic methods.

Unmet Clinical Need:




Over 12M biopsy procedures are performed yearly to detect cancer. Biopsies are invasive, random, slow, cover limited tissue areas, and often miss pre-cancerous cells.

In spite of these limitations, biopsies are widely used in attempts to detect cancer, at considerable cost to patient care and comfort.


Cancer Survival:

Cancer survival is severely limited due to delayed detection and treatment. In the case of esophageal cancer, the 5-year survival rate is only 16%. In 2009 there were 16,470 cases of esophageal cancer diagnosed and 14,530 deaths.



Early detection of esophageal cancer cannot be reliably achieved with existing diagnostic methods that rely on the random biopsy of limited tissue areas.

Cancer Detection Methods:



The Oncoscope Advantage:

Oncoscope addresses a key critical need of cancer diagnosis: providing early detection in combination with broad tissue coverage.


The Oncoscope optical imaging system:

- Is non-invasive;
- Provides immediate results;
- Examines early stage cancer and pathology;
- Monitors large tissue areas;
- Requires no contrast agents.

Technology & Products:

Enlarged cell nuclei are a key marker used by pathologists to identify pre-cancerous and cancerous cells. Oncoscope's proprietary technology, developed at Duke University, analyzes scattered light to measure the size of cell nuclei.

The Oncoscope SCOBE-E product locates pre-cancerous cells in the esophagus. SCOBE-E is fast and accurate in animal and laboratory tests. This platform technology will be applied to the early detection of cancer in the colon, lung, and cervix.



Market: \$24 B is spent each year in the U.S. to detect cancerous epithelial tissue. In fact, \$4.0 B is spent for esophageal endoscopy alone, a market targeted by Oncoscope's first product, the SCOBE-E system. Procedure cost is driven by the number of biopsies, each of which requires individual pathology examination.

Oncoscope plans to address this market by:

- increasing the number of patients being screened for cancer;
- improving early detection of cancer through guided biopsy; and
- connecting diagnosis with immediate treatment.

Clinical & Regulatory: The Oncoscope technology has been tested in 34 patients to date and has shown 100% sensitivity and 87% specificity in detecting dysplasia in esophageal tissue. Further, Oncoscope is the recipient of an SBIR grant for a 2-year, 200 patient multicenter clinical study beginning October 2009. The Company is pursuing a 510(k) clearance with a limited indication-for-use as well as a Pre-Market Approval to support use as a guide to conventional biopsy tissue selection. CE marking is also being pursued in parallel with these US filings.

Intellectual Property: Oncoscope has developed five patent families to date, including U.S. and foreign applications, directed to devices and methods for various optical imaging systems. The first two patent families, exclusively licensed from Duke University, cover the key innovations for determining cell nuclei size in multiple tissue layers from a single data collection event using scattered light. Broad claims have recently issued in the US for the core technology involved in determining cell nuclear size.

Management Team:

Perry A. Genova, Ph.D., CEO
John Autrey, CFO
Gary Pace, Ph.D., Esq.
Corporate Counsel

Directors:

Adam Wax, Ph.D., Founder
Dan Pelak,
Former CEO, Closure Medical
Matthew Megaro,
Former CEO, Quill Medical
Lister Delgado,
IDEA Fund Partners

Scientific Advisor:

Nicholas Shaheen, MD, MPH
UNC School of Medicine

Key Shareholders:

Duke University
IDEA Fund Partners
Southeast TechInventures

Company Information: Founded in June, 2006 by Dr. Adam Wax and Dr. William Brown based on optical imaging technologies developed by Dr. Wax at the Dept of Biomedical Engineering at Duke University with support from Duke, the National Cancer Institute, the National Science Foundation and the Wallace H. Coulter Foundation.

Visit www.oncoscope.com for relevant publications and technical information.

Oncoscope, Inc. 324 Blackwell St. Suite 1120 Durham, NC 27701 919-251-8030 info@oncoscope.com